Researchers in the US and Canada have made a breakthrough in the fight against Ebola haemorrhagic fever, one of the world's deadliest diseases caused by the Ebola virus, by successfully testing several Ebola vaccines in primates.
Dr Anthony Sanchez, from the Centers for Disease Control and Prevention in Atlanta, Georgia and colleagues are looking to adapt the vaccines for human use.
"The biothreat posed by Ebola virus cannot be overlooked. We are seeing more and more naturally occurring human outbreaks of this deadly disease. With worldwide air travel and tourism the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism", said Dr Sanchez.
"We desperately need a protective vaccine," he added.
Until now, there have been over 1500 cases of Ebola haemorrhagic fever in humans. Illness starts suddenly and symptoms include fever, headache, sore throat, weakness, joint and muscle aches, diarrhoea, vomiting and stomach pain. A rash, red eyes and bleeding may also occur. Ebola haemorrhagic fever can have a mortality rate of around 90 percent in humans.
Because Ebola virus is so dangerous, producing and testing a vaccine is extremely challenging for the scientists. One noteworthy factor slowing down progress has been that there are only a very limited number of high containment facilities with staff capable and authorised to conduct the research.
"Ebola virus is a Biosafety Level 4 threat, along with many other haemorrhagic fever viruses", said Dr Sanchez.
"As well as the difficulty in getting the right staff and facilities, vaccines for viruses like Ebola, Marburg and Lassa fever have been difficult to produce because simple 'killed' viruses that just trigger an antibody response from the blood are not effective. For these viruses we need to get a cell-mediated response, which involves our bodies producing killer T-cells before immunity is strong enough to prevent or clear an infection," he added.
Dr Sanchez and his team have now used several different recombinant DNA techniques, which have allowed them to trigger a cell-mediated response and produce a vaccine that is effective in non-human primates. One of the candidate vaccines is about to be tested on people for the first time, after entering Phase 1 clinical trials in autumn 2006.
"Ebola virus infection of humans can be highly lethal but monkeys rarely survive the infection and have been very useful as animal models. Ebola vaccine trials using nonhuman primates have provided unambiguous results and have allowed the development of protective vaccines to progress rapidly", said Dr Sanchez.
"Successful human trials will mean that we can vaccinate healthcare workers and other key personnel during outbreaks of Ebola haemorrhagic fever, helping us to protect their lives and control the spread of the disease," he added.
The researchers hope that the findings from their studies will provide important insights that will improve or speed up the future development of vaccines for other haemorrhagic fever viruses like Marburg virus, and agents such as HIV and avian influenza.
Dr Sanchez will present an overview of Ebola vaccine development at the Society for General Microbiology's 162nd meeting being held this week at the Edinburgh International Conference Centre.